AstraZeneca Provides Update on P-III (AMPLIFY) Trial of Calquence for Treating Chronic Lymphocytic Leukemia
Shots:
- The P-III (AMPLIFY) study is assessing the safety & efficacy of Calquence (BTK inhibitor) + venetoclax, with/without obinutuzumab, vs SoC chemoimmunotherapy in treatment-naïve CLL adults without del(17p) or TP53 mutation
- Interim analysis of the study depicted improved PFS and immature OS data, though a favorable trend towards the combination was observed, its evaluation is underway9
- Safety profile & tolerability aligned with the known safety outcomes without any new concerns; low cardiac toxicity was seen. Data will be highlighted at future conferences and shared with regulatory bodies worldwide
Ref: AstraZeneca | Image: AstraZeneca
Related News:- AstraZeneca Showcases the P-III (ECHO) Study Data of Calquence Combination Regimen for Mantle Cell Lymphoma at EHA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
